National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Late Effects of Treatment for Childhood Cancer (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 03/26/2008
Table 6. Hepatic Late Effects*

Late Effects  Causative Treatment   Signs and Symptoms  Screening and Diagnostic Tests  Management and Intervention 
*Adapted from Schwartz et al.[34]
Hepatic fibrosis/cirrhosis Chemotherapy: methotrexate, actinomycin D, 6-MP, 6-thioguanine (6-TG) Itching, jaundice, spider nevi, bruising, portal hypertension, esophageal varices, hemorrhoids, hematemesis, encephalopathy Height and weight each year, CBC, reticulocytes, platelets, each year; liver function studies every 2–5 years (hepatic screen, liver biopsy, endoscopy) Hepatitis screen (hepatitis A, B, C/ cytomegalovirus [CMV]), diuretics, liver transplant, varices, sclerosis, vascular shunting
Radiation: >30 Gy
Surgery: Massive resection

References

  1. Schwartz C L, Hobbie WL, Constine LS, et al., eds.: Survivors of Childhood Cancer: Assessment and Management. St. Louis, Mo: Mosby, 1994. 


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov